Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study.
The aim of this study was to investigate the effects of tandospirone on ataxia in various types of spinocerebellar degeneration (SCD). Fifteen milligram per day of tandospirone was administered to 39 patients with SCD (spinocerebellar atrophy (SCA) 1, five patients; SCA2, six patients; Machado-Joseph disease (MJD), 14 patient; SCA6, five patients; multiple system atrophy-cerebellar type (MSA-C), seven patients; and multiple system atrophy-Parkinson type (MSA-P), two patients). All patients were assessed before and 4 weeks after administration of the drug using the international cooperative ataxia rating scale total score (ARS), total length traveled (TLT) of body stabilometry, and a self-rating depression scale. Statistically, ARS showed a significant difference in MJD (p = 0.005) and SCA6 (p = 0.043). TLT also showed a significant difference in MJD (p = 0.002) and SCA6 (p = 0.043). Eight of 39 patients (SCA1, 1/5; SCA2, 0/6; MJD, 4/14; SCA6, 3/5; MSA-C, 0/7; and MSA-P, 0/2) showed more than a five point reduction in ARS, and 13 of 39 patients (SCA1, 0/5; SCA2, 1/6; MJD, 8/14; SCA6, 4/5; MSA-C, 0/7; and MSA-P, 0/2) showed a reduction of TLT. Our data indicate that the effects of tandospirone on ataxia are different between types of SCD. Therefore, tandospirone is useful for cerebellar ataxia in patients with MJD and SCA6.
Takei
Asako
A
Hokuyukai Neurology Hospital, Niju-yon-ken 2-2-4-30, Nishi-ku, Sapporo, 063-0802, Japan. atakei@med.hokudai.ac.jp
Hamada
Shinsuke
S
Homma
Sanae
S
Hamada
Keiko
K
Tashiro
Kunio
K
Hamada
Takeshi
T
D000328:Adult; D000368:Aged; D001259:Ataxia / Q000188:drug therapy* / Q000209:etiology*; D003863:Depression / Q000139:chemically induced; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D013132:Spinocerebellar Degenerations / Q000145:classification / Q000150:complications*
D054833:Isoindoles; D010879:Piperazines; D011743:Pyrimidines; D017366:Serotonin Receptor Agonists; C055267:tandospirone
J Neurol Sci. 2007 Sep 15;260(1-2):143-6
17512011
Front Mol Neurosci. 2009 Dec 11;2:29
20076763
Arch Neurol. 1988 Nov;45(11):1217-22
3190503
Neurology. 1994 Jul;44(7):1302-8
8035935
Cerebellum. 2005;4(3):211-5
16147954
Arch Neurol. 1995 Oct;52(10):982-8
7575226
Eur J Pharmacol. 1988 Jan 5;145(1):31-8
2965025
Psychiatry Clin Neurosci. 2002 Apr;56(2):181-5
11952922
Clin Neuropharmacol. 2004 Jan-Feb;27(1):9-13
15090930
Acta Neurol Scand. 2003 Mar;107(3):207-10
12614314
Nihon Rinsho. 1999 Apr;57(4):805-10
10222770
J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):86-9
10369828
J Neurol Sci. 1999 Feb 1;163(1):94-8
10223419
J Neurol Sci. 1997 Feb 12;145(2):205-11
9094050
J Neurochem. 1996 Jan;66(1):203-9
8522955